2023 Strong Foundations, Brighter Tomorrow
Building a strong foundation - Day 1
Faculty - Prof Sarah Jarvis, Prof Christoph Wanner, Prof Jennifer Green, Prof Kausik Ray
Building a strong foundation - Day 2
Faculty - Prof Sarah Jarvis, Prof Christoph Wanner, Prof Jennifer Green, Prof Kausik Ray
Solutions for the Cardio-Renal-Metabolic conundrum
Faculty - Dr Anita Sharma, Prof Andrew Coats, Dr Ted Wu, Dr Janaka Karalliedde, Dr Bobby Chacko
Start Today for a Brighter Tomorrow – Day 1
Faculty - Prof Stephan Jacob, Dr Camilo Aquino, Prof Merlin Thomas, Dr Ted Wu
Start Today for a Brighter Tomorrow – Day 2
Faculty - Prof Stephan Jacob, Dr Camilo Aquino, Prof Merlin Thomas, Dr Ted Wu
2022 Organ Protection Starts Now
It's Time to Act
Nothing can reverse damaged Heart and Kidney. Join our webinar and explore Organ protection.
The many benefits of SGLT2i
HbA1c lowering is no longer enough! Explore the many benefits of SGLT2is from reduction to protection.
CRM Summit - The gift that keeps on giving
Reduction (HbA1c, weight, blood pressure) to protection (Heart and Kidneys), and MORE? Give SGLT2i that keeps on giving to your patients.
Don’t wait till it’s too late
It's too late to protect kidneys once the disease progresses. Don't wait!
Protect at first sight
We can’t afford to delay organ protection. Protect your patients at first sight!
2021 Break Cardio-Renal-Metabolic-Continuum
ASIAN CRM FORUM: Sugar, Salt and Water: A Recipe for Disaster?
Connect and Protect series 1 VN webinar.
NEWLY DIAGNOSED T2D: Opportunity to Protect Early
Connect and Protect series 2 ID webinar.
ADVANCED T2D: Act to Help Protect Maximally
Connect and Protect series 3 KR webinar.
Overcoming the Challenges of a Broken Heart
Connect and Protect series 5 MYSG webinar.
ASIAN CRM INTERCHANGE: Sugar, Salt and Water at Bay: Keep A Disaster Away
Connect and Protect series 6 TH webinar.
PC-MY-102932
×
- Please click the timestamp to watch topic you are interested in.
- 00:00 Introduction
- “It’s Time to Act” – What is the urgency - 9:45 Glucose perspective - 19:20 Heart perspective - 38:07 Kidney perspective
- “Start Early” – Overcoming clinical inertia - 49:26 What are the words we should use to convey the sense of urgency? - 58:20 What are practical considerations before initiating SGLT2i? What to expect, what to monitor? - 1:07:55 How do you decide between SGLT2i or GLP1 RA? - 1:11:32 Is it safe to use SGLT2i in lean individuals?
- “Meet the Experts” – Live Q&A - 1:17:18 When would ACC/AHA HF guideline be updated? - 1:20:09 What should we do with patients with T2D without albuminuria, low eGFR without albuminuria and T2D? - 1:23:42 Could SGLT2i be beneficial on eyes as they are beneficial on heart and kidneys? - 1:26:46 Is improving ejection fraction a goal of HF or reducing syndrome? - 1:31:56 DKA, Sick-day rules - 1:37:15 How low eGFR is safe to start and continue? - 1:40:50 Would you initiate eGFR for patients with HF and dialysis? Transplant? - 1:43:14 Would SGLT2i be beneficial to reduce new diabetes? - 1:48:02 UTI, GTI - 1:49:35 SGLT2i and GLP1-RA have any benefit in fatty liver disease? What is connection?
- 1:51:30 Take 5 summary
- Please click the timestamp to watch topic you are interested in.
- 00:00 Introduction
- “An apple a day to keep diabetes at bay” – Going beyond glucose with SGLT2i - 5:56 Old strategies – and their benefits - 10:45 New medications – better chances - 20:09 New medications include a paradigm shift - 25:42 Take home message
- “An apple a day to keep diabetes at bay” – How do they work - 28:35 The mechanism for kidney protection
- “Making the evolution of diabetes management a revolution” – Panel discussion - 47:55 Patient case introduction - 50:24 What should we have done with this patient? - 53:33 Risk factor management or Organ protection management? - 57:50 How to overcome inertia that SGLT2i would not work in patients eGFR below 45?
- “Meet the Experts” – Live Q&A - 59:19 Putting cost aside, would you consider SGLT2i as first line therapy? - 1:00:55 Which would you start GLP1 RA vs SGLT2i? - 1:03:48 Where does it lead metformin in management of T2D? - 1:05:58 How concerned are we about hypoglycemia with SGLT2i? - 1:09:01 What is the risk of DKA? - 1:12:20 Is there any intercurrent events disturb patients i.e. stroke, AKI? - 1:14:13 Is there a threshold of GFR drop? - 1:16:21 Are there any other ways to look at kidney damage? - 1:19:45 If a patient is already on metformin and DPP4i, would you stop that or add SGLT2i? - 1:21:13 Are there patients where you have to reduce anti-hypertensive medication? Or elderly or frail patients? - 1:23:10 How do you manage GTI? How frequently you see it? - 1:25:57 Do you have any advices in Asian patients with GLR and body weight levels in the use of SGLT2i? - 1:26:48 Is it something to consider in patients with ketogenic diet, impermanent fasting or fasting period?
- 1:28:52 Take 5 summary
- Please click the timestamp to watch topic you are interested in
- 00:00 Introduction
- 9:46 Organ protection at the heart of T2D management by Prof. Thomas
- Panel Discussion: Diabetes – Organ Protection is everyone’s responsibility 22:17 Patient case introduction
- Meet the Experts: Q&A session 43:29 SGLT2i class effect? 48:01 What does “Early” patient mean? High risk? 50:55 How to intervene early? Recommended eGFR or UACR? 56:18 GLP1 RA for high BMI, high ASCVD risk, high UACR?
- 1:01:29 SGLT2i: beyond the glucose lowering effects 1:24:03 Panel Discussion: Gift the gift that protects failing hearts 1:44:40 Meet the Experts: Q&A session 2:03:12 Take 5 summary
- Please click the timestamp to watch topic you are interested in
- 00:00 Introduction
- 5:22 Providing hope for diabetic kidney disease by Prof Rossings Panel Discussion: Don’t wait till it’s too late 35:31 Major points to highlight from the talk 37:36 Gap between evidence and practice, what are the main barriers? 45:14 Perceived safety of SGLT2i & how to use SGLT2i in which eGFR? 48:34 Monitoring of renal function when you start SGLT2 49:39 How should we be looking for HF early? Meet the Experts & Q&A session 54:16 Should we use different dose of Empagliflozin in T2D and in HF? 55:37 SGLT2i concerns around hypoglycemia? 58:55 Perception around SGLT2is’ metabolic effects 1:04:02 Newly diagnosed patients need to be on SGLT2i without managing A1c? 1:06:19 What is guidance of using SGLT2i in acute HF/Kidney disease setting? 1:14:47 Do SGLT2is improve albuminuria? Class effect? 1:17:10 Mechanism of action of SGLT1? 1:18:31 Should statin be included in T2D patients even if their cholesterol level is normal? 1:19:57 Do SGLT2is cause polyuria? Role of Cystatin c to better manage CKD? 1:21:58 Relative and absolute risk reduction of SGLT2i around prophylaxis for future heart failure events? 1:24:30 For patients with T2D whose glucose is controlled but with risk factors for kidney disease, should SGLT2i be added? 1:25:57 Take 5 summary
- Please click the timestamp to watch topic you are interested in
- 00:00 Introduction
- 3:47 How does the burden of heart failure compare with other chronic illnesses? by Prof Park 15:06 How can we improve the identification of patients at risk so that appropriate preventive measures are initiated the soonest? by Prof Park 28:38 How are we doing in managing HF which was first described as an emerging epidemic about 25 years ago? by Prof Böhm 41:18 How can we provide optimal organ protection to our heart failure patients the moment we see them? by Prof Böhm 51:45 As a new treatment option, how does SGLT-2 inhibition/empagliflozin fit into the heart failure management considerations? by Prof Böhm
- Meet the Experts & Q&A session 1:02:01 Is there any difference in treatment effect among SGLT2i above EF>60% compared to <60%? 1:05:28 Are there any concerns in initiating SGLT2i in renal transplant patients? 1:06:47 Do you think SGLT2 in post MI patient to reduce the remodeling of LV? 1:12:14 Is there a role of GLP1 molecule in Heart failure and improve mortality? 1:15:03 Is there any priority in managing comorbidity for fragile elderly HFpEF patients?
- 1:20:31 Take 5 summary
- Please click the timestamp to watch topic you are interested in
- 0:00Opening Dr Kavitha
- 3:55Session introduction Prof Stephan Jacob
- 16:24 Cardiovascular disease prevention in diabetes: an achievable goal? Dr Camilo Aquino
- 37:22:00 Expert’s consultProf Stephan Jacob
Dr Camilo Aquino - 43:34:00 Start today for a brighter tomorrow Prof Merlin Thomas
- 1:04:17 Expert’s consult
Prof Stephan Jacob
Prof Merlin Thomas - 1:11:47 Live Q and A All
- 1:34:23 Case discussion: Early intervention with organ protective therapies All
- 2:02:26 Take 5 key messages and Closing for Day 1 Prof Stephan Jacob
- Please click the timestamp to watch topic you are interested in
- 0:00 Session introduction and recap of Day 1 Prof Stephan Jacob
- 4:50 Start and step up early in T2D Dr Ted wu
- 25:05 Expert’s consult Prof Stephan Jacob
Dr Ted wu - 34:47 Case discussion: Start and step up earlyAll
- 58:27 Live Q and A All
- 1:17:37 Panel discussion: Holistic person-centred care All
- 1:36:59 Live Q and A All
- 1:50:47 Take 5 key messages and Closing for Day 2 Prof Stephan Jacob
×
